Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor

202175 citationsJournal Articlegold Open Access

Authors

Dan You · Bristol-Myers Squibb (United States)

Stephen Hillerman · Bristol-Myers Squibb (United States)

Gregory Locke · Bristol-Myers Squibb (United States)

Charu Chaudhry · Johnson & Johnson (United States)

Caitlyn Stromko · Bristol-Myers Squibb (United States)

Anwar Murtaza · Bristol-Myers Squibb (United States)

Yi Fan

Abstract

CompK treatment significantly improved human T-cell functions, with enhanced TCR avidity to recognize TAAs and tumor cytolytic activity by CD8+ T cells. Additional benefits include DC maturation and priming facilitation in tumor draining lymph node. CompK represents a novel pharmacological agent to address cancer treatment resistance.

Topics & Keywords

Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 9, Issue 1, pp. e001402-e001402

DOI: 10.1136/jitc-2020-001402

Field-Weighted Citation Impact: 4.77